By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
INTRODUCTION
Ezetimibe/simvastatin is a drug combination used for the treatment of dyslipidemia. It is a combination of ezetimibe (known as Zetia in the United States) and the statin drug simvastatin (known as Zocor in the US).Ezetimibe reduces blood cholesterol by acting at the brush border of the small intestine and inhibiting the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver.
Simvastatin is an HMG-CoA reductase inhibitor or statin. It works by blocking an enzyme that is necessary for the body to make cholesterol. Generic versions were approved. The combination preparation is marketed by Merck & Co. under the trade names Vytorin in the US and Inge in the European Union. In the previous years , it was the top most commonly prescribed medication in the United States, with more than eight hundred thousand prescriptions.
The combination of ezetimibe and simvastatin is currently the only product to treat both sources of cholesterol; absorption in the intestine of both biliary and dietary cholesterol, and production in the liver and peripheral tissues. It is thought that the treatment of high cholesterol from both sources is likely to result in lower cholesterol levels, particularly LDL cholesterol. In a clinical study, it was shown that the combination of ezetimibe and simvastatin was superior to atorvastatin in lowering LDL cholesterol.
EZETIMIBE AND SIMVASTATIN MARKET SIZE AND FORECAST
The Global Ezetimibe and Simvastatin Market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
EZETIMIBE AND SIMVASTATIN MARKET NEW PRODUCT LAUNCH
CIPLA ezetimibe and simvastatin Ezetimibe reduces the amount of cholesterol absorbed by the body. Simvastatin is in a group of drugs called HMG CoA reductase inhibitors, or “statins.
“Ezetimibe and simvastatin is a combination medicine that is used to lower blood levels of “bad” cholesterol (low-density lipoprotein, or LDL), to increase levels of “good” cholesterol (high-density lipoprotein, or HDL), and to lower triglycerides (a type of fat in the blood).
Ezetimibe and simvastatin is used together with a low-fat diet and other treatments to lower total cholesterol in adults and children who are at least 10 years old. It is not known whether ezetimibe and simvastatin reduces your risk of heart disease.
EZETIMIBE AND SIMVASTATIN MARKET COMPANY PROFILE
THIS EZETIMIBE AND SIMVASTATIN MARKET REPORT WILL ANSWER FOLLOWING QUESTIONS
